Stem cell centres in UAE, Israel sign agreement

Stem cell centres, UAE, Israel, sign agreement

Abu Dhabi - It was signed by Emirati and Israeli representatives from both companies during a ceremony held via videoconference.

By Wam

Published: Mon 17 Aug 2020, 9:00 PM

Last updated: Tue 18 Aug 2020, 8:10 AM

Two of the most dynamic and promising players in the stem cells field in UAE and Israel have signed a pact to cooperate in the research to combat Covid-19 virus.
The agreement between Abu Dhabi Stem Cells Centre (ADSSC) and Pluristem Therapeutics Inc. will pave the way for collaboration in research and development of services and products related to regenerative medicine. It was signed by Emirati and Israeli representatives from both companies during a ceremony held via videoconference.
"The UAE has always been inclusive in its approach to finding solutions to global challenges, bringing together the many competencies of people from diverse countries," said Dr Fatima Al Kaabi, executive director of the Abu Dhabi Bone Marrow Transplant programme. "We at ADSCC have followed suit, as is evident in the diversity of expertise among my colleagues and our international partners."
Dr Yendry Ventura, general manager of ADSCC, said: "Pluristem have proven themselves to be formidable players in the stem cells field and we look forward to working together with great excitement."
Both the ADSCC and Pluristem have developed innovative products that have proven safe and effective in treating Covid-19 infections. Pluristem has treated patients with its placental PLX-PAD allogenic product via compassionate use programs in Israel and the US and currently is conducting phase II studies in the US and EU.
The ADSCC has been treating Covid-19 patients with its patented and approved UAECell19 product which has shown, relative to standard treatment, clinical improvement in half the usual time and reduction in the length of hospital stays to about a quarter of the average duration. The parties have agreed to exchange research results, share samples, join usage of equipment and testing, and other essential activities related to advancing the treatment and research of cell therapies for a broad range of medical conditions, including Covid-19.
Yaki Yanai, CEO and president of Pluristem, said: "We are extremely proud to partner with our colleagues at the ADSCC by sharing knowledge and expertise that will advance healthcare within and across our borders. We see life science and regenerative medicine as a bridge for building peace, prosperity, and well-being in our region and for the entire world. I believe it is our obligation and privilege as business and scientific leaders to lead the way forward to strengthen collaborations, and promote innovation and education."

More news from